Topiramate and the risk of urolithiasis

BJU International

Volumn 107, Issue 3, 2011, Pages 352-354

  Hanchanale, Vishwanath S ^a   Biyani, Chandra Shekhar ^b   Browning, Anthony J ^b   Joyce, Adrian D ^c  

^a District Hospital   (United Kingdom)

^b PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TOPIRAMATE; ZONISAMIDE;

ABNORMAL URINE COMPOSITION; CENTRAL NERVOUS SYSTEM DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG MECHANISM; EPILEPSY; HUMAN; HYPOCITRATURIA; KETOGENIC DIET; METABOLIC ACIDOSIS; NEPHROLITHIASIS; NOTE; PARESTHESIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STAGHORN STONE; UROLITHIASIS; WEIGHT REDUCTION;

CARBONIC ANHYDRASE INHIBITORS; FRUCTOSE; HUMANS; MIGRAINE DISORDERS; RISK FACTORS; UROLITHIASIS;

EID: 79251551979     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09953.x     Document Type: Note

References (27)

1. Walker MC, Sander JW,. Topiramate: A new antiepileptic drug for refractory epilepsy. Seizure 1996; 5: 199-203
2. Sachdeo RC,. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 1998; 34: 335-46
3. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943-50
4. McIntyre RS, Riccardelli R, Binder C, Kusumakar V,. Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 2005; 50: 415-22
5. Nickel C, Lahmann C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: A randomized, double-blind, placebo-controlled study. J Affect Disord 2005; 87: 243-52
6. Arnone D,. Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 2005; 4: 5
7. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004; 291: 965-73
8. D'Amico D, Grazzi L, Usai S, Moschiano F, Bussone G,. Topiramate in migraine prophylaxis. Neurol Sci 2005; 26 (Suppl 2): s130-3
9. Topiramate: New preparation. Helpful in refractory partial epilepsy. Prescrire Int 1999; 8: 3-5
10. Faught E,. Topiramate in the treatment of partial and generalized epilepsy. Neuropsychiatr Dis Treat 2007; 3: 811-21
11. Rosenfeld WE,. Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19: 1294-308
12. Natsch S, Hekster YA, Keyser A, Deckers CL, Meinardi H, Renier WO,. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 1997; 17: 228-40
13. Chung S, Wang N, Hank N,. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007; 16: 296-304
14. Wasserstein AG, Rak I, Reife RA,. Nephrolithiasis during treatment with topiramate. Epilepsia 1995; 36 (Suppl 3): 153
15. Jones MW,. Topiramate-safety and tolerability. Can J Neurol Sci 1998; 25: S13-5
16. Holland KD, Wyllie PE,. Use of topiramate in localization-related epilepsy in children. J Child Neurol 2000; 15 (Suppl 1): S3-6
17. Goyal M, Grossberg RI, O'Riordan MA, Davis ID,. Urolithiasis with topiramate in nonambulatory children and young adults. Pediatr Neurol 2009; 40: 289-94
18. Vega D, Maalouf NM, Sakhaee K,. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf 2007; 6: 547-57
19. Lamb EJ, Stevens PE, Nashef L,. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004; 41: 166-9
20. Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE,. Topiramate-induced nephrolithiasis. J Endourol 2002; 16: 229-31
21. Warner BW, LaGrange CA, Tucker T, Bensalem-Owen M, Pais VM Jr,. Induction of progressive profound hypocitraturia with increasing doses of topiramate. Urology 2008; 72: 29-32; discussion 32-3
22. Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K,. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 2006; 48: 555-63
23. AlarÄ?on-Martínez H, Casas-Fernández C, Escudero-Rodríguez N, et al. Nephrolithiasis and topiramate. Rev Neurol 2006; 42: 91-4
24. Lõpez-Real AM, García-Antelo MJ, Fernández-Couto D, Lõpez-Facal S, Rubio-Nazabal E,. Staghorn calculus secondary to topiramate. Farm Hosp 2008; 32: 299-300
25. Paul E, Conant KD, Dunne IE, et al. Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. Epilepsy Res 2010; 90: 151-6
26. Kossoff EH, Pyzik PL, Furth SL, Hladky HD, Freeman JM, Vining EP,. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002; 43: 1168-71
27. Mirza N, Marson AG, Pirmohamed M,. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol 2009; 68: 655-61